-
Gynecologie, Obstetrique, Fertilite &... Sep 2023
Topics: Humans; Female; Prophylactic Mastectomy; Mastectomy; Breast Neoplasms; Robotics; Mastectomy, Segmental
PubMed: 37019213
DOI: 10.1016/j.gofs.2023.03.008 -
The Surgical Clinics of North America Dec 2021Breast surgical oncology is a rapidly evolving field with significant advances shaped by practice-changing research. Three areas of ongoing controversy are (1) high... (Review)
Review
Breast surgical oncology is a rapidly evolving field with significant advances shaped by practice-changing research. Three areas of ongoing controversy are (1) high rates of contralateral prophylactic mastectomy (CPM) in the United States despite uncertain benefit, (2) indications for and use of neoadjuvant chemotherapy (NACT) and endocrine therapy (NET), and (3) staging and treatment of the axilla, particularly after neoadjuvant systemic therapy. We discuss the patient populations for whom CPM may or may not be beneficial, indications for NACT and NET, and the trend toward de-escalation of locoregional axillary treatment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Axilla; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Mammaplasty; Mastectomy; Neoadjuvant Therapy; Neoplasm Staging; Prophylactic Mastectomy
PubMed: 34774266
DOI: 10.1016/j.suc.2021.06.002 -
Annals of Surgical Oncology Nov 2023
PubMed: 37633854
DOI: 10.1245/s10434-023-14161-4 -
Gland Surgery Jan 2021Contralateral prophylactic mastectomy (CPM) rates have continued to rise in the United States, impacting all stakeholders including plastic and reconstructive surgeons.... (Review)
Review
Contralateral prophylactic mastectomy (CPM) rates have continued to rise in the United States, impacting all stakeholders including plastic and reconstructive surgeons. Multiple factors may be influencing this trend, including patient decision-making characteristics, knowledge about breast cancer disease and prognosis, advances in genetic testing and enhanced imaging capabilities, sociodemographic factors, and access to specialty surgical services such as breast reconstruction. In this review, the authors shed light on the current state of CPM and summarize the literature analyzing its increasing prevalence in the United States, as well as outline future directions for study and dissemination of knowledge from providers to patients surrounding this important and complex treatment decision.
PubMed: 33634008
DOI: 10.21037/gs.2020.03.15 -
Annals of Surgical Oncology Sep 2021
Topics: Breast Neoplasms; Female; Genetic Testing; Humans; Mammaplasty; Mastectomy; Prophylactic Mastectomy
PubMed: 33796999
DOI: 10.1245/s10434-021-09892-1 -
JAMA May 2021
Topics: Adult; Breast; Breast Neoplasms; Female; Germ-Line Mutation; Humans; Prophylactic Mastectomy; Risk Factors; Risk Reduction Behavior
PubMed: 33944884
DOI: 10.1001/jama.2020.22414 -
Biochimica Et Biophysica Acta. Reviews... Jul 2023The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene, including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and... (Review)
Review
The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene, including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and influences a patient's individualized treatment options. BRCA1/2 mutation (BRCAm) increases the risk of breast cancer. However, breast-conserving surgery is still an option for BRCAm, and prophylactic mastectomy and nipple-sparing mastectomy may also reduce the risk of breast cancer. BRCAm is sensitive to Poly (ADP-ribose) polymerase inhibitor (PARPi) therapy due to specific types of DNA repair defects, and its combination with other DNA damage pathway inhibitors and endocrine therapy and immunotherapy are also used for the treatment of BRCAm breast cancer. The current treatment and research progress of BRCA1/2 mutant breast cancer in this review provides a basis for the individualized treatment of patients with this type of breast cancer.
Topics: Humans; Female; Breast Neoplasms; BRCA1 Protein; BRCA2 Protein; Mastectomy; Antineoplastic Agents; Poly(ADP-ribose) Polymerase Inhibitors; Mutation
PubMed: 37172654
DOI: 10.1016/j.bbcan.2023.188907